Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with cirrhosis (scarring of the liver) from any cause, confirmed by a liver biopsy, imaging scans, clinical signs such as fluid in the abdomen or swollen veins in the food pipe, or a special liver stiffness test
- People considered to be at high risk of developing liver cancer, based on one or more of the following: a current active hepatitis C infection, a blood test result called FIB-4 of 3.25 or higher (taken within the last 6 months), or an estimated annual liver cancer risk above 2.5% calculated using a specific risk tool (taken within the last 6 months)
- People aged between 18 and 75 years old
- People who are able to give their informed consent to participate
Who may not be able to join:
- People who have previously been diagnosed with liver cancer, or where liver cancer is currently suspected
- People who have previously received an organ transplant, or who are currently on a waiting list for one
- People who are already taking part in another liver cancer screening trial
- People with severely reduced liver function, defined by specific medical scoring systems (Child-Pugh score of 10 or above, or MELD score above 20, within the last 6 months) (confirm with trial site)
- People whose kidneys are not working well enough, specifically a kidney filtration rate below 30 ml/min
- People with multiple serious health conditions that are expected to significantly shorten life expectancy, based on a specific scoring tool — though early-stage cancers of the bladder, lung, or prostate do not automatically exclude someone (confirm with trial site)
- People whose life expectancy is estimated to be less than 5 years, as judged by the study doctor
- People who are unable to safely have a contrast-enhanced MRI scan, including those with: an allergy to the contrast dye used in MRI, certain implanted medical devices such as pacemakers or defibrillators, implanted nerve stimulators, cochlear (ear) implants, implanted drug pumps, metal objects in or near the eyes, metal fragments in the body such as bullets or shrapnel, non-removable metal body piercings, certain brain artery clips, severe claustrophobia (fear of enclosed spaces), or a body weight above 400 lbs that makes fitting in the MRI machine difficult
- People who are unlikely to be able to attend all planned study visits, for example due to living too far away or having no transport
- People who are currently pregnant
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: George N. Ioannou, MD MS, VA Puget Sound Health Care System Seattle Division, Seattle, WA
Phone: (206) 277-3136
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Hepatocellular Carcinoma Mortality
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.